Market research
NECLIFE.NSE Nectar Lifesciences Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 42
- Dividend yield
- Not available
- Beta
- 0.65
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE023H01027
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 42
- Dividend yield
- Not available
- Beta
- 0.65
About
About Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Further. It exports its poducts. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NECLIFE.NSE discussion.
5 years, 5 months ago
Nectar Lifesciences Limited is currently in a long term uptrend where the price is trading 86.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Nectar Lifesciences Limited's total revenue sank by 41.7% to $4B since the same quarter in the previous year.
Its net income has dropped by 198.2% to $-81M since the same quarter in the previous year.
Finally, its free cash flow fell by 135.8% to $-382M since the same quarter in the previous year.
Based on the above factors, Nectar Lifesciences Limited gets an overall score of 2/5.